PharmaBio Corporation
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Clinical Study of PAL-222 Targeting Patients With Refractory Skin Ulcer (NCT07016438) | PharmaBio Corporation | 2025-04-15 |
| Progression Suppression and Retinal Regression in VEGF-resistant AMD (NCT07005323) | PharmaBio Corporation | 2024-09-12 |
| Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA) (NCT05658237) | PharmaBio Corporation | 2023-02-17 |
Track PharmaBio Corporation automatically
Every clearance here is in the API, with alerts when new ones post.